Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation
1. The purpose of this study is to determine the efficacy of ramosetron for the prevention of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic treatment during hematopoietic stem cell transplantation
2. The study hypothesis is that ramosetron is effective for the prevention of emesis and control of emesis and/or vomiting that develop after the prophylactic antiemetic therapy in the setting of hematopoietic stem cell transplantation
Hematologic Malignancies
DRUG: ramosetron
efficacy of ramosetron in terms of complete response (no emesis, no rescue therapy) during the conditioning regimen and within 3 or 6 days after the end of the conditioning regimen, within 1 week after the end of conditioning regimen
the efficacy of second dose of ramosetron for the treatment of breakthrough emesis, within 1 week after the end of conditioning regimen
the number of vomiting episodes, within 1 week after the end of conditioning regimen|grade of nausea and need for rescue therapy, within 1 week after the end of conditioning regimen
1. The purpose of this study is to determine the efficacy of ramosetron for the prevention of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic treatment during hematopoietic stem cell transplantation
2. The study hypothesis is that ramosetron is effective for the prevention of emesis and control of emesis and/or vomiting that develop after the prophylactic antiemetic therapy in the setting of hematopoietic stem cell transplantation